AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27601592
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no systematic treatment)
Trial: 17337369
Drug: Preemptive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive local infiltration (PLA) with 20 mL of 0.2% ropivacaine diluted with 80 mL of 0.9% saline (total volume 100 mL)
Trial: 17337369
Drug: Postoperative wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative wound infiltration (POW) of 20 mL of 0.2% ropivacaine (40 mg)
Trial: 15529256
Drug: Parenteral influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral influenza vaccination
Trial: 11297828
Drug: 10 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/70 kg (iv) morphine
Trial: 10027666
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.i.d. for two weeks
Trial: 10027666
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg q.i.d. for two weeks
Trial: 11583639
Drug: Oral antimicrobials
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antimicrobials
Trial: 8085732
Drug: Topical antipseudomonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical antipseudomonal agents
Trial: 61340
Drug: Intravenous oxprenolol
RxNorm normalized name: oxprenolol
DrugBank: Oxprenolol (DB01580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxprenolol
Trial: 61340
Drug: Control studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control studies (no drug)
Trial: 26355616
Drug: CO2 facial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 facial treatment
Trial: 17058830
Drug: Sodium ferulate
RxNorm normalized name: ferulate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferulate (SF) 300 mg/d intravenously for 4 weeks
Trial: 17058830
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including dietary therapy and hypodermic injection of insulin
Trial: 14762655
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day for 12 months
Trial: 11519354
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide cream (generic drug)
Trial: 11519354
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide cream (brand name)
Trial: 11519354
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control (no active treatment)
Trial: 7853678
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) administered at a dose of 60-90 mg/kg divided into 3 dosages via 30-minute intravenous drip infusion
Trial: 7853678
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) at a dose of 20 mg/kg via 30-minute intravenous drip infusion
Trial: 7853678
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) at a dose of 10 mg/kg via 30-minute intravenous drip infusion
Trial: 7853678
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) at doses of 20 and 10 mg/kg via 30-minute intravenous infusion
Trial: 7853678
Drug: Cefozopran (CZOP)
RxNorm normalized name: cefozopran
DrugBank: Cefozopran (DB13667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefozopran (CZOP) administered to patients with various infections
Trial: 24649780
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (MgSO4) 50 mg kg(‐1) in 10 mL within 10 min, followed by an infusion of MgSO4 10 mg kg(‐1) hr(‐1) IV in 4mL for 12 hrs
Trial: 20358154
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulphate (MgSO4)
Trial: 14701947
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg) and tinidazole (600 mg) combination twice daily for 7 days (Group 1)
Trial: 14701947
Drug: Fluconazole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (150 mg), azithromycin (1 gm) and secnidazole (2 mg) as one time dose (Group 2)
Trial: 14701947
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg twice daily) and metronidazole (200 mg thrice daily for 7 days (Group 3)
Trial: 11124072
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine indices of benefit and harm
Trial: 9070501
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg dolasetron mesylate
Trial: 9070501
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dolasetron mesylate
Trial: 9070501
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dolasetron mesylate
Trial: 9070501
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dolasetron mesylate
Trial: 8348504
Drug: Intravesical epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical epirubicin (50 mg per instillation)
Trial: 8348504
Drug: Bacillus Calmette-Guérin
RxNorm normalized name: Bacillus Calmette-Guérin (BCG) vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus Calmette-Guérin (BCG) (150 mg per instillation)
Trial: 2948430
Drug: Salbutamol (0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.02 mL/kg of a 0.5% solution)
Trial: 2948430
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (2 mL of a 0.025% solution)
Trial: 2948430
Drug: Salbutamol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol plus ipratropium combination
Trial: 2948430
Drug: Half-dose or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose or full-dose combinations of salbutamol and ipratropium
Trial: 25914397
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with zotarolimus-eluting stents
Trial: 25917626
Drug: Phleum pratense
RxNorm normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phleum pratense subcutaneous immunotherapy (6 weekly doses)
Trial: 25917626
Drug: Phleum pratense
RxNorm normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phleum pratense subcutaneous immunotherapy (8 weekly doses)
Trial: 25917626
Drug: Phleum pratense
RxNorm normalized name: PHLEUM PRATENSE
DrugBank: Phleum pratense pollen (DB10394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phleum pratense subcutaneous immunotherapy (eight doses, two clustered increasing doses over 3 weeks)
Trial: 20975274
Drug: Topiramate at
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate at a mean dose of 200 mg/day
Trial: 20975274
Drug: Naltrexone at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone at a mean dose of 50 mg/day
Trial: 1414298
Drug: Sodium sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium sucrose sulphate solution
Trial: 31499238
Drug: Hand gel
RxNorm normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL GEL [Hand Gel]
DrugBank: Triclosan (DB08604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hand gel sanitizer
Trial: 30423587
Drug: Placebo (physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (physical therapies alone, n=112)
Trial: 26420517
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill with sedative information
Trial: 21987409
Drug: TachoSil (collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TachoSil (collagen patch coated with human coagulation factors)
Trial: 12124856
Drug: Low-dose extract
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose extract of Tripterygium wilfordii Hook F (180 mg/day)
Trial: 12124856
Drug: High-dose extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose extract of Tripterygium wilfordii Hook F (360 mg/day)
Trial: 12124856
Drug: Open-label extension
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label extension (Low-dose)
Trial: 12124856
Drug: Open-label extension
RxNorm normalized name: BOTTLE OPENER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label extension (High-dose)
Trial: 10466239
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy with conventional regimens
Trial: 7573018
Drug: Traditional Dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Dialysate (TD; ionized calcium concentration 1.75 mmol/L)
Trial: 7573018
Drug: Low Calcium
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Calcium Dialysate (LCD; ionized calcium concentration 1.25 mmol/L)
Trial: 6783346
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg as a micronized powder with lactose
Trial: 6783346
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg as micropellets without lactose
Trial: 6783346
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (SCG) 20 mg as an aerosol
Trial: 17877506
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy options
Trial: 10404803
Drug: Cisapride 10
RxNorm normalized name: cisapride 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 10 mg 4 times daily for 8 weeks
Trial: 26887207
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received lower dose anesthetics (Fentanyl 250 μg + Flurbiprofen axetil 25 mg + normal saline 2 mL/h, Sauteralgyl if necessary)
Trial: 21949005
Drug: Target treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target treatment group (2 hours of therapy and coaching each week)
Trial: 21949005
Drug: Community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community treatment group (variety of services averaging 3.9 hours per week)
Trial: 21949005
Drug: Target treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target treatment group
Trial: 19702088
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI) after surgical operation and chemotherapy (group C)
Trial: 14561016
Drug: Cardioselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta-blockers (single dose)
Trial: 14561016
Drug: Cardioselective beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta-blockers (longer duration)
Trial: 10898408
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg) plus ISMN (20 mg twice a day)
Trial: 10898408
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (50 mg) plus GTN (500 microg)
Trial: 10898408
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus ISMN (20 mg twice a day)
Trial: 8599314
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (153 micromol or 10 mg Zn/d)
Trial: 2856902
Drug: Nadolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (40 mg twice a day)
Trial: 31113277
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (mean dose: 622.0 mg/day)
Trial: 17445921
Drug: Adjunctive corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive corticosteroids (used by 109 patients, 58.9%)
Trial: 17445921
Drug: Non-use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-use of adjunctive corticosteroids
Trial: 8732558
Drug: Mother's own
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mother's own milk with multivitamin supplement with iron
Trial: 6613525
Drug: Gamma-vinyl-GABA (GVG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-vinyl-GABA (GVG) 1 g per day
Trial: 6613525
Drug: Gamma-vinyl-GABA (GVG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-vinyl-GABA (GVG) 2 g per day
Trial: 6613525
Drug: Gamma-vinyl-GABA (GVG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-vinyl-GABA (GVG) 3 g per day
Trial: 29908417
Drug: Nilotinib (NIL)
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib (NIL) 800 mg/day (Cohort 1)
Trial: 29908417
Drug: High-dose imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose imatinib (IM) 800 mg/day (Cohort 2)
Trial: 29908417
Drug: Sustained standard-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained standard-dose imatinib (IM) 400 mg/day (Cohort 3)
Trial: 27502710
Drug: Standard paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard paclitaxel at 200 mg/m(2) (arm A)
Trial: 27502710
Drug: PK-guided dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PK-guided dosing of paclitaxel (arm B)
Trial: 24833327
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (NAC) 600 mg bid
Trial: 18813043
Drug: Low-dose dexmedetomidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexmedetomidine (loading, 3 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.2 microg x kg(‐1) x h(‐1) for 60 min)
Trial: 18813043
Drug: High-dose dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexmedetomidine (loading, 6 microg x kg(‐1) x h(‐1) for 10 min; maintenance, 0.4 microg x kg(‐1) x h(‐1) for 60 min)
Trial: 11968583
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha monotherapy (3 million u. three times per week until signs of relapse)
Trial: 11968583
Drug: Sequence administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence administration of interferon alpha and dexamethasone (40 mg on days 1-4, 10-13, and 20-23, followed by interferon alpha after a four-week interval until disease progression)
Trial: 11968583
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha monotherapy or dexamethasone (preference question)
Trial: 11968583
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment overall
Trial: 2181588
Drug: Levodopa (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (mean dose: 485 ± 71 mg daily)
Trial: 2181588
Drug: Bromocriptine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (mean dose: 55 ± 6 mg daily)
Trial: 394755
Drug: Aminophylline suppositories
RxNorm normalized name: Aminophylline Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline suppositories
Trial: 394755
Drug: Slow-release aminophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release aminophylline tablets
Trial: 30821115
Drug: DP-VPA 1200
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DP-VPA 1200 mg
Trial: 25678838
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic with steroid with lumbar interlaminar approach
Trial: 25678838
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic with steroid with caudal approach
Trial: 17298590
Drug: Self-management-oriented programme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management-oriented programme (treatment B)
Trial: 17298590
Drug: Didactic‐oriented training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didactic‐oriented training programme (treatment A)
Trial: 17298590
Drug: More individualized
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More individualized approach (treatment C)
Trial: 11220982
Drug: Sildenafil (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (all doses combined)
Trial: 8821690
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate (3.6 mg every 28 days)
Trial: 8821690
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (300 mg/day)
Trial: 8821690
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of goserelin acetate and cyproterone acetate
Trial: 1444298
Drug: Teicoplanin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (100 mg twice a day for 10 days)
Trial: 6138597
Drug: Vancomycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (500 mg four times a day for 10 days)
Trial: 26879791
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Finasteride + Tamsulosin)
Trial: 20454855
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) d,l-MPH 20 mg
Trial: 20454855
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) d,l-MPH 20 mg
Trial: 17432644
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of pepsin mixture
Trial: 11851868
Drug: Cerivastatin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerivastatin (0.2 mg daily for 6 weeks, then increased to 0.4 mg if LDL-C did not decrease below 3.0 mmol x L(-1))
Trial: 11851868
Drug: Fenofibrate (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (250 mg daily)
Trial: 9861907
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention program (early surgery, minimal narcotic analgesia, intense daily therapy, close monitoring)
Trial: 7595907
Drug: Fludrocortisone 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone 0.8 mg daily for 7 days (short protocol)
Trial: 7595907
Drug: Fludrocortisone (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (1.4 nmol/l) in vitro
Trial: 7595907
Drug: Fludrocortisone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone treatment
Trial: 21118281
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg intravenously)
Trial: 19489487
Drug: Electroacupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture at Fenglong (ST 40) with parameters: 50 Hz, 1 mA for TG type (20 min, twice/week); 100 Hz, 1 mA for CHO type (30 min, thrice/week); same as CHO for LDL-C type; alternating methods for mixing type.
Trial: 19489487
Drug: Xuezhikang capsule,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang capsule, 2 capsules twice daily for 11 weeks.